Clinical Read2026-06-01

RP1 (vusolimogene oderparepvec) and OPDIVO (nivolumab) - (IGNYTE-3)

Replimune Group Inc.REPL
Indication
Non-melanoma (NMSC) / Non-small cell lung cancer (NSCLC)
Stage
phase3
Event
Phase 3